Gaziя A. Sachautdinov

Gaziя A. Sachautdinov

Auto-generated profile, based on publicly available information

Gaziя A. Sachautdinov

Saint Petersburg State Pediatric Medical University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2025 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
SKS. A. Kulyova
S. A. Kulyova
SVS. R. Varfolomeeva
S. R. Varfolomeeva
KKKirill Kirgizov
Kirill Kirgizov
EPElizaveta Prosekina
Elizaveta Prosekina
ORO. M. Romantsova
O. M. Romantsova
NMN. V. Matinyan
N. V. Matinyan
Background. In the literature, information on the overexpression of disialoganglioside GD2 on the cells of malignant neoplasms is not uncommon. In this regard, this marker should be considered as a tumor-associated antigen, which may be a target on the cell surface in patients with poor prognosis.The aim of the study – improve the efficacy of the treatment of children and adolescents with refractory and recurrent solid malignancies (soft tissue, undifferentiated (unSA) and bone sarcomas) by incorporating targeted immunotherapeutic options (immunotherapy with antiGD2 monoclonal antibodies (MA)) into comprehensive therapy programs.Materials and methods. Ten patients with GD2-positive relapsed/refractory soft tissue sarcomas (STS, n = 4), osteosarcomas (OS, n = 2), Ewingʼs sarcomas (ES, n = 4) and unSA (n = 1) were included in the study. The gender ratio was 2.3:1 (boys:girls). The mean age at the time of inclusion in the study was 12 ± 2 years. The most of all patients (80 %) had a status of “primary resistant disease”. GD2 quantitative expression level was 29 ± 11 % (0.9 to 85 %). Patients were represented by deeply pretreated patients who received 8 to 25 cycles of 2+ line chemotherapy (mean 13). A total of 7 patients completed the full reinduction treatment (6 cycles of chemoimmunotherapy). All patients received anti-GD2 MA 100 mg/m2 as an intravenous 5-day infusion every 4 weeks, and treatment was continued until disease progression or 6 cycles. Fifty-two cycles of immunotherapy were performed.Results. Pain syndrome was the most frequently diagnosed (after 16 cycles, or in 30.7 % of cases); 5 (9.6 %) cycles each were accompanied by diarrhea, cytokine release syndrome, and increased capillary permeability syndrome. The immediate results varied according to the histological subtype of the tumor. The overall objective response rate was 43 % (3/7): 2 patients achieved complete remission (CR) and one achieved partial remission (PR). The disease control rate (CR + PR + stable) was 86 % (6/7). The clinical response rate 6 months after completion of chemoimmunotherapy ranged from 0 % (2/2) in ES to 50 % (1/2) in OS. In 43 % (3/7) of evaluable patients, disease progression was diagnosed after a mean of 5 months. At follow-up after 12 and 24 months, CR persisted in all patients with STS (100 %). Progression-free survival (PFS) in patients with STS at 6, 12 and 24 months was 100 % (PFS6, PFS12, PFS24, respectively). PFS6 in OS and ES patients was 100 % and 50 %, respectively, gradually decreasing to 0 %. The study revealed a very strong positive straight-line positive functional correlation between quantitative GD2 expression and progression-free survival (r = 0.971, p = 0.00006).Conclusion. Passive immunotherapy with monoclonal antibodies is a safe treatment method without severe immune-related adverse reactions. Patient follow-up and evaluation of the efficacy and safety of the drug after the end of the therapy plan continues until today, which allows a more detailed and objective evaluation of the results of immunotherapy according to the purpose of the study.

30 June 2023 in Voprosy onkologii
Verified
Journal Article
Open access
PDF file
СКСветлана Кулева
Светлана Кулева
КБКсения Борокшинова
Ксения Борокшинова
ИБИрина Балдуева
Ирина Балдуева
ТНТатьяна Нехаева
Татьяна Нехаева
AAAnna Artemyeva
Anna Artemyeva
ГСГазиз Сахаутдинов
Газиз Сахаутдинов
Diffuse high-grade glioma is the most common highly malignant primary brain tumor with an extremely aggressive growth and an unfavorable prognosis. The article describes a clinical case of a 10-year-old child with diffuse midline glioma, H3 K27M-mutant, who after standard chemoradiotherapy is designed as a maintenance therapy for a dendritic cell vaccine based on immunogenic carcinotesticular and GD2 antigens (CTA+ (cancer-testis antigen) GD2+ (ganglioside) vaccine). Tumor lysate was represented by glioblastoma cell culture with 96% GD2 expression. GM-CSF (granulocyte-macrophage colony-stimulating factor), IL4 (interleukin 4) and FNOα (tumor necrosis factor α) were used as the growth and differentiation factors of dendritic cells derived from peripheral blood monocytes. Multitargeted immunotherapy with CTA+GD2+ vaccine apriori solves the evolution problem of phenotypic heterogeneity and has greater clinical and immunological efficacy in high-grade gliomas with their gradual immunoediting. Диффузная глиома высокой степени злокачественности (high-grade глиома) — наиболее часто встречающаяся высокозлокачественная первичная опухоль головного мозга с крайне агрессивным течением и неблагоприятным прогнозом. В статье описывается клинический случай 10-летнего ребенка с диффузной срединной глиомой головного мозга с альтерацией в гене H3 K27, которому после стандартного химиолучевого лечения в качестве поддерживающей терапии создан дендритноклеточный вакцинный препарат на основе иммуногенных раковотестикулярных и GD2 антигенов [(CTA+ (cancer-testis antigen) GD2+ (ganglioside)] вакцина). Опухолевый лизат был представлен глиобластомной клеточной культурой с экспрессией GD2 96%. В качестве ростовых и дифференцировочных факторов дендритных клеток, полученных из моноцитов периферической крови, были ГМ-КСФ (гранулоцитарно-макрофагальный колониестимулирующий фактор), ИЛ4 (интерлейкин 4) и ФНОα (фактор некроза опухоли α). Мультитаргетная иммунотерапия CTA+GD2+ аутологичной ДК-вакциной априори решает эволюционную проблему фенотипической гетерогенности и обладает большей клинической и иммунологической эффективностью в отношении high-grade глиом с их постепенным иммуноредактированием.

16 May 2026 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Closed access
SKSvetlana A. Kulyova
Svetlana A. Kulyova
VKVadim A. Khashuro
Vadim A. Khashuro
EBEkaterina Gennadjievna Batotsyrenova
Ekaterina Gennadjievna Batotsyrenova
GSGaziя A. Sachautdinov
Gaziя A. Sachautdinov
YSYulia K. Semenova
Yulia K. Semenova
OSOlga E. Savyelyeva
Olga E. Savyelyeva
Currently, immuno-oncology is a rapidly developing field of medicine, primarily due to the integration of achievements in molecular biology and biotechnology (creation and production of modified cells and effector molecules), immunological physiology (understanding of subtle mechanisms of regulation of immune functions) and clinical medicine (adequate accompanying therapy, allowing manipulation of the patient’s immune system). A large number of tumors overexpress tumor-associated gangliosides (sialylated glycosphingolipids). For example, GD3, GD2 and GM2 are overexpressed in melanoma and neuroblastoma cells, increased expression of GD1a, GM1, GM2 is shown in carcinoma cells, GD2 is expressed by soft tissue sarcoma, osteogenic sarcoma and small cell lung cancer cells. The ratio of the number of gangliosides varies from one tumor type to another. In addition, gangliosides are found in neoplastic tissues that are not characteristic of normal transformed cells of this tissue. In particular, one such ganglioside is GD2. In normal cells, the expression of this ganglioside, as well as that of GM2, is restricted to nerve cells, but in the case of cancer transformation they are found in cells of malignant tumors. Numerous studies have shown that tumor-associated gangliosides arising from oncogenic transformation play a key role in invasion and metastasis of a number of tumors and induce tumor-associated angiogenesis. First of all, it has been established that tumor cells differ in the composition of gangliosides. the ganglioside composition of metastasis cells differs from the cells of the primary tumor focus and is characterized by a decrease in the content of complex gangliosides. Due to its high level of expression in a number of tumors and limited expression in normal tissues, ganglioside GD2 can be considered as an ideal potential target for the development of anti-tumor immunotherapies.